SLU-PP-332 (C18H14N2O2) is a synthetic pan-estrogen-related receptor (ERRα/β/γ) agonist with highest potency for ERRα (EC50 ∼98 nM), classified as a next-generation exercise mimetic. Unlike traditional fat burners that stimulate CNS, SLU-PP-332 directly activates the ERRα/PGC-1α master transcriptional pathway for energy metabolism without hormonal stimulation. It is the top trending compound for endurance performance and VO2 max research, metabolic syndrome and obesity models with insulin resistance, skeletal muscle oxidative remodeling studies, and protocols investigating mitochondrial dysfunction and fatty liver.
SLU-PP-332 drives metabolic effects through four sequential cellular steps. 1. ERRα ACTIVATION: SLU-PP-332 binds ligand-binding domain of ERRα (Estrogen-Related Receptor α), stabilizes active conformation & coactivates PGC-1α (PPARγ coactivator-1α), master transcriptional regulator for energy metabolism. 2. MITOCHONDRIAL BIOGENESIS: Upregulates PGC-1α → NRF1/2 & TFAM signaling, increases mitochondrial replication & mass, boosts OXPHOS complex proteins & electron transport chain CI-CV. 3. FATTY ACID OXIDATION & METABOLISM: Upregulates CPT1, MCAD, ACADM enzymes for β-oxidation, enhances lipid uptake & oxidation in mitochondria, ↑Acetyl-CoA → TCA Cycle → ATP Production, increased oxidative phosphorylation & cellular respiration. 4. MUSCLE FIBER SWITCHING & METABOLIC OUTPUT: Shifts muscle fibers: Glycolytic Type IIb → Oxidative Type IIa/I (Low Mitochondria → High Mitochondria), ↑oxidative capacity & exercise endurance, ↑metabolic rate & energy expenditure. Physiologic Outcome: Enhanced exercise endurance, improved glucose tolerance, reduced fat mass. Cellular Effect: ↑Mitochondrial density, ↑ATP production, ↑oxygen consumption. Metabolic Benefit: Exercise-mimetic effect, ↑metabolic rate, potential for metabolic syndrome therapy. Preclinical research shows SLU-PP-332 acts as exercise mimetic via ERRα/PGC-1α axis and increases oxidative phenotype in skeletal muscle.
Our SLU-PP-332 lineup is supplied as high-purity powder (>99% HPLC) with COA. For injectable and oral research, we offer SLU-PP-332 10mg (starter), SLU-PP-332 20mg (standard - most requested), SLU-PP-332 50mg (high-dose value) vials, and oral bioavailable SLU-PP-332 Capsules 250mcg x 60, 500mcg x 60, and 1000mcg x 60 for daily dosing models. SLU-PP-332 belongs to Fat Metabolism Peptides category alongside AOD 9604 and MOTS-c, but uniquely acts via mitochondrial biogenesis rather than lipolysis directly. Commonly stacked with MOTS-c 5mg (mitochondrial peptide) and 5-Amino-1MQ 50mg (NNMT inhibitor) for comprehensive metabolic rate protocols. Stable 24 months at -20°C. For Research Use Only, not for human consumption.